HCW Biologics

HCW Biologics is a clinical-stage biopharmaceutical company developing novel immunotherapies for chronic, low-grade inflammation and related diseases. Its pipeline includes HCW9302, an injectable IL-2 fusion protein complex in clinical trials for alopecia areata; HCW11-018b, a tetra-valent T-cell engager; and multifunctional fusion molecules combining cytokines with checkpoint blockade. The company also develops reagents for NK-cell and CAR-therapy production under licensing arrangements with partners such as Wugen and WY Biotech.